全文获取类型
收费全文 | 6280篇 |
免费 | 428篇 |
国内免费 | 137篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 169篇 |
妇产科学 | 206篇 |
基础医学 | 763篇 |
口腔科学 | 175篇 |
临床医学 | 791篇 |
内科学 | 1496篇 |
皮肤病学 | 160篇 |
神经病学 | 351篇 |
特种医学 | 417篇 |
外科学 | 780篇 |
综合类 | 192篇 |
预防医学 | 221篇 |
眼科学 | 163篇 |
药学 | 438篇 |
中国医学 | 40篇 |
肿瘤学 | 424篇 |
出版年
2023年 | 24篇 |
2022年 | 66篇 |
2021年 | 116篇 |
2020年 | 78篇 |
2019年 | 95篇 |
2018年 | 148篇 |
2017年 | 115篇 |
2016年 | 132篇 |
2015年 | 246篇 |
2014年 | 228篇 |
2013年 | 258篇 |
2012年 | 388篇 |
2011年 | 376篇 |
2010年 | 260篇 |
2009年 | 181篇 |
2008年 | 289篇 |
2007年 | 342篇 |
2006年 | 278篇 |
2005年 | 267篇 |
2004年 | 248篇 |
2003年 | 306篇 |
2002年 | 270篇 |
2001年 | 212篇 |
2000年 | 182篇 |
1999年 | 144篇 |
1998年 | 91篇 |
1997年 | 89篇 |
1996年 | 74篇 |
1995年 | 69篇 |
1994年 | 62篇 |
1993年 | 62篇 |
1992年 | 110篇 |
1991年 | 79篇 |
1990年 | 87篇 |
1989年 | 91篇 |
1988年 | 77篇 |
1987年 | 75篇 |
1986年 | 64篇 |
1985年 | 42篇 |
1984年 | 28篇 |
1983年 | 31篇 |
1982年 | 26篇 |
1981年 | 27篇 |
1980年 | 16篇 |
1979年 | 32篇 |
1978年 | 20篇 |
1977年 | 26篇 |
1976年 | 19篇 |
1973年 | 16篇 |
1972年 | 17篇 |
排序方式: 共有6845条查询结果,搜索用时 15 毫秒
61.
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. 总被引:12,自引:0,他引:12
Thorir D Bjornsson John T Callaghan Heidi J Einolf Volker Fischer Lawrence Gan Scott Grimm John Kao S Peter King Gerald Miwa Lan Ni Gondi Kumar James McLeod R Scott Obach Stanley Roberts Amy Roe Anita Shah Fred Snikeris John T Sullivan Donald Tweedie Jose M Vega John Walsh Steven A Wrighton 《Drug metabolism and disposition》2003,31(7):815-832
Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism and Clinical Pharmacology Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers. 相似文献
62.
63.
Phase II trial of gefitinib in recurrent glioblastoma. 总被引:13,自引:0,他引:13
Jeremy N Rich David A Reardon Terry Peery Jeannette M Dowell Jennifer A Quinn Kara L Penne Carol J Wikstrand Lauren B Van Duyn Janet E Dancey Roger E McLendon James C Kao Timothy T Stenzel B K Ahmed Rasheed Sandra E Tourt-Uhlig James E Herndon James J Vredenburgh John H Sampson Allan H Friedman Darell D Bigner Henry S Friedman 《Journal of clinical oncology》2004,22(1):133-142
PURPOSE: To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS: This was an open-label, single-center phase II trial. Fifty-seven patients with first recurrence of a glioblastoma who were previously treated with surgical resection, radiation, and usually chemotherapy underwent an open biopsy or resection at evaluation for confirmation of tumor recurrence. Each patient initially received 500 mg of gefitinib orally once daily; dose escalation to 750 mg then 1,000 mg, if a patient received enzyme-inducing antiepileptic drugs or dexamethasone, was allowed within each patient. RESULTS: Although no objective tumor responses were seen among the 53 assessable patients, only 21% of patients (11 of 53 patients) had measurable disease at treatment initiation. Seventeen percent of patients (nine of 53 patients) underwent at least six 4-week cycles, and the 6-month event-free survival (EFS) was 13% (seven of 53 patients). The median EFS time was 8.1 weeks, and the median overall survival (OS) time from treatment initiation was 39.4 weeks. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent at higher doses. Withdrawal caused by drug-related adverse events occurred in 6% of patients (three of 53 patients). Although the presence of diarrhea positively predicted favorable OS from treatment initiation, epidermal growth factor receptor expression did not correlate with either EFS or OS. CONCLUSION: Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma. Further study of this agent at higher doses is warranted. 相似文献
64.
Koeneman KS Kao C Ko SC Yang L Wada Y Kallmes DF Gillenwater JY Zhau HE Chung LW Gardner TA 《World journal of urology》2000,18(2):102-110
65.
Jun-Jun Yeh Wu-Huei Hsu We-Tao Huang Jhi-Joung Wang Shung-Tai Ho Albert Kao 《Tumour biology》2003,24(3):151-155
The multidrug resistance gene 1 encoding human P-glycoprotein (Pgp) is thought to play an important role in the multidrug resistance of lung cancer. The purpose of this study was to predict chemotherapy response by technetium-99m tetrofosmin (Tc-99m TF) lung single photon emission computed tomography (SPECT) and compare Pgp expression in patients with untreated small cell lung cancer (SCLC). Forty patients with untreated SCLC received Tc-99m TF lung SPECT prior to chemotherapy. The chemotherapy response was evaluated in the 3rd month after completion of treatment. Immunohistochemical staining of Pgp expression was performed on multiple nonconsecutive sections of biopsy specimens. By quantitative analyses, tumor to background ratios were 1.86 +/- 0.27 and 1.17 +/- 0.26 for patients with a good and poor response, respectively (p < 0.05). All of the 20 patients with a good chemotherapy response also had a positive Tc-99m TF lung SPECT and negative Pgp expression. In contrast, only 4 of the 20 patients with a poor chemotherapy response had a positive Tc-99m TF lung SPECT. Moreover, 10 of the 20 patients with a poor chemotherapy response also had negative Pgp expression (p < 0.05). Therefore, we concluded that Tc-99m TF lung SPECT can accurately predict the chemotherapy response, and Tc-99m TF lung SPECT findings can be partially compatible with Pgp expression in patients with untreated SCLC. 相似文献
66.
Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study 总被引:11,自引:0,他引:11
Context Although the excess prevalence of type 2 diabetes mellitus in African Americans is well established, few studies have compared incident diabetes in African American and white persons. Objectives To compare risk of incident diabetes in African American vs white adults and to identify explanatory factors for racial disparities. Design Prospective cohort study using baseline data collected from 1986 to 1989 from the ongoing Atherosclerosis Risk in Communities (ARIC) Study, with 9 years of follow-up. Setting and Participants A total of 2646 African American and 9461 white adults aged 45 to 64 years without diabetes at baseline, sampled from 4 US communities. Main Outcome Measures Incident type 2 diabetes, ascertained by self-report of physician diagnosis, use of diabetes medications, or fasting glucose level of at least 7.0 mmol/L (126 mg/dL), compared among white and African American subjects and by presence of potentially modifiable risk factors. Results Diabetes incidence per 1000 person-years was about 2.4-fold greater in African American women (25.1 [95% confidence interval {CI}, 22.4-28.1] vs 10.4 [95% CI, 9.4-11.4]) and about 1.5-fold greater in men (23.4 [95% CI, 19.9-27.2] vs 15.9 [95% CI, 14.6-17.2]) than in their white counterparts (P<.001). Results from proportional hazards regression models indicated that racial differences in potentially modifiable risk factors, particularly adiposity, accounted for 47.8% of the excess risk in African American women but accounted for little excess risk in African American men. Compared with their white counterparts, African American men and women had higher blood pressures before diabetes onset (diastolic blood pressure difference=5.6 mm Hg in women and 8.4 mm Hg in men; P=.005). Conclusions Our data indicate that compared with their white counterparts, middle-aged African Americans are at greater risk of developing type 2 diabetes and have higher blood pressure prior to development of diabetes. In women, almost 50% of this excess risk might be related to potentially modifiable factors. 相似文献
67.
68.
69.
艾灸足三里治疗顺铂所致迟发性呕吐的临床观察 总被引:9,自引:0,他引:9
目的:观察艾灸足三里治疗顺铂所致迟发性呕吐的临床效果.方法:100例患者随机分A、B两组各50例,A组(治疗组):枢星3mg 0.9%NS20ml化疗前30min iv d1-3 艾灸足三里d1-7;B组(对照组):枢星3mg 0.9%NS20ml化疗前30min iv d1~3,观察化疗后7d内呕吐情况.结果:A组控制迟发性呕吐的有效率明显高于B组(P<0.05).结论:艾灸足三里治疗顺铂所致迟发性呕吐疗效好、经济、方便、安全. 相似文献
70.
Postero-medio-anterior approach of the ankle for the pilon fracture 总被引:17,自引:0,他引:17
A good view of the operative field is important for better reduction and fixation in surgical treatment of fractures. The exposure of the ankle joint for the pilon fracture is commonly through the anterior approach, or combined with the medical approach. But sometimes it is still difficult to have complete viewing of the articular surface and to apply internal fixation by that approach. In recent years, we developed a "postero-medio-anterior" approach of the ankle joint by one incision. This approach provides an excellent exposure of the anterior, medial and posterior aspects of the ankle joint with a clear view of the articular surface. In our 45 cases of pilon fracture during 1991 to 1995, there was no incisional injury to the neurovascular bundle. Superficial wound edge necrosis was noted in two cases which healed later without further procedure. Therefore, we recommend this approach as a simple and reliable incision for open reduction of pilon fractures. 相似文献